首页> 外文期刊>Experimental and clinical transplantation >The Effects of Compound Danshen Dripping Pills and Human Umbilical Cord Blood Mononuclear Cell Transplant After Acute Myocardial Infarction
【24h】

The Effects of Compound Danshen Dripping Pills and Human Umbilical Cord Blood Mononuclear Cell Transplant After Acute Myocardial Infarction

机译:复方丹参滴丸与人脐血单个核细胞移植对急性心肌梗死的影响

获取原文
       

摘要

Objectives: The low frequency of survival of stem cells implanted in the myocardium after acute myocardial infarction may be caused by inflammation and oxidative stress in the myocardial microenvironment. We evaluated the effects of a traditional Chinese medicine, Compound Danshen Dripping Pills, on the cardiac microenvironment and cardiac function when used alone or in combination with human umbilical cord blood mononuclear cell transplant after acute myocardial infarction. Materials and Methods: After surgically induced acute myocardial infarction, rabbits were treated with Compound Danshen Dripping Pills alone or in combination with human umbilical cord blood mononuclear cell transplant. Evaluation included histology, measurement of left ventricular ejection fraction and fractional shortening, leukocyte count, count of green fluorescent protein positive cells, superoxide dismutase activity, and malondialdehyde content. Results: Combination treatment with Compound Danshen Dripping Pills and human umbilical cord blood mononuclear cell transplant significantly increased the survival of implanted cells, inhibited cardiac cell apoptosis, decreased oxidative stress, decreased the inflammatory response, and improved cardiac function. Rabbits treated with either Compound Danshen Dripping Pills or human umbilical cord blood mononuclear cells alone had improvement in these effects compared with untreated control rabbits. Conclusions: Combination therapy with Compound Danshen Dripping Pills and human umbilical cord blood mononuclear cells may improve cardiac function and morphology after acute myocardial infarction.
机译:目的:急性心肌梗死后植入心肌的干细胞存活率低可能是由于心肌微环境中的炎症和氧化应激引起的。我们评估了中药复方丹参滴丸对急性心肌梗死患者单独使用或与人脐血单核细胞移植联合使用时对心脏微环境和心脏功能的影响。材料与方法:手术诱发急性心肌梗死后,单独或与人脐带血单核细胞移植联合用复方丹参滴丸治疗家兔。评价包括组织学,左心室射血分数和分数缩短,白细胞计数,绿色荧光蛋白阳性细胞计数,超氧化物歧化酶活性和丙二醛含量。结果:复方丹参滴丸与人脐带血单核细胞移植联合治疗可显着提高植入细胞的存活率,抑制心脏细胞凋亡,降低氧化应激,降低炎症反应并改善心脏功能。与未治疗的对照兔相比,仅用复方丹参滴丸或人脐带血单核细胞治疗的兔在这些作用上都有改善。结论:复方丹参滴丸与人脐血单个核细胞联合治疗可改善急性心肌梗死后的心脏功能和形态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号